Treatment of Hereditary Angioedema "Notification"
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity criteria, site-of-care rules, dosing maximums, and continuation criteria for restricted HAE therapies (Berinert, Cinryze, Ruconest, Kalbitor, Firazyr/generic icatibant/Sajazir) including documentation requirements and limitations on concurrent anti-HAE agents.
Reformatted diagnostic criteria to align HAE type I and II with updated guidelines and renamed HAE type III to HAE with normal C1-INH with updated diagnostic requirements.
For acute treatments, removed requirement that patient must be experiencing at least one symptom of a moderate or severe HAE attack and adjusted placement of symptom examples.
Added Sajazir (branded generic of Firazyr) to policy under existing J1744 HCPCS code.
For brand Firazyr, Sajazir, and Ruconest, added requirement of trial and failure of generic icatibant within initial and continuation criteria.
Added requirement for use of self-administered product unless criteria for inability to self-administer are met.
For Cinryze continuation criteria, added required documentation confirming prophylactic use and demonstration of clinical benefit.
Added requirement that medications known to cause angioedema have been evaluated and discontinued when appropriate.
Added requirement to be prescribed by or in consultation with a specialist.
Adjusted maximum units for products.
Updated Site of Care criteria to add bypasses for patients with history of severe adverse events or conditions that increase risk for severe adverse events.
Coverage Summary
This policy covers the treatment of hereditary angioedema (HAE) with specified restricted medications and is covered with criteria. It defines medical necessity requirements for FDA‑approved HAE therapies (Berinert, Cinryze, Ruconest, Kalbitor, Firazyr/generic icatibant/Sajazir), includes product‑specific age minimums and indication distinctions between prophylaxis and acute treatment, requires documentation of diagnostic complement testing and prior therapies when applicable, applies maximum unit limits and Site‑of‑Care rules for injections/infusions, and requires specialist prescribing or consultation. The policy effective date is 2026-04-01, last reviewed 2026-04, and is maintained by Blue Cross NC (policy reviewed annually by the Blue Cross NC P&T Committee).
Medical Necessity Criteria (Initial & Continuation)
Provider Actions & Documentation Requirements
Prior authorization required
Prior authorization is required. Requests must document diagnostic complement testing (C4, C1‑INH antigen, and C1‑INH function as applicable), indicate product-specific age and intended use (prophylaxis vs acute), report prior therapies (including trial of generic icatibant when applicable), document inability to self‑administer if requesting a non‑self‑administered formulation, and confirm the patient will not be treated with more than one anti‑HAE agent for the same purpose. Affected HCPCS codes: J0597, J0598, J0596, J1290, J1744.
- Diagnostic tests: C4, C1‑INH antigen, C1‑INH function (as applicable).
- Document indication-specific age and whether use is prophylaxis or acute.
- Report prior therapies (e.g., generic icatibant trial when required).
- Document inability to self-administer if seeking non‑self‑administered product.
- Confirm no concurrent anti‑HAE agent for same purpose.
Medical record documentation required
Medical record documentation must include laboratory values and, when applicable, genetic testing or family history to support the HAE subtype. If HAE‑nl‑C1INH is claimed, document genetic testing confirming a causative mutation or family history plus recurring angioedema refractory to high‑dose second‑generation H1 antihistamines (4x standard dose) for at least one month. Document trials/failures of required therapies (e.g., generic icatibant when applicable), evaluation and discontinuation of medications known to cause angioedema (ACE inhibitors, ARBs, DPP‑IV inhibitors, estrogens, neprilysin inhibitors), and examples demonstrating attack severity for acute treatment or evidence of clinical benefit for prophylaxis (e.g., decreased attack frequency or decreased use of on‑demand therapy).
- Required labs: C4, C1‑INH antigen (protein), C1‑INH function (activity) as applicable.
- HAE‑nl‑C1INH: genetic testing confirming causative mutation OR family history plus recurring attacks refractory to high‑dose H1 antihistamine (4x) for ≥1 month.
- Document trial/failure of therapies when required (e.g., generic icatibant for certain brands).
- Document evaluation and discontinuation of angioedema‑causing medications (ACEi, ARB, DPP‑IV inhibitors, estrogens, neprilysin inhibitors).
- Provide examples of attack severity (airway swelling, severe abdominal pain, facial swelling, etc.) or clinical benefit for prophylaxis (reduced attack frequency or decreased on‑demand use).
Quantity limits and maximum units
Requested quantity must not exceed the product‑specific maximum units allowed for the duration of approval. See the policy's maximum units table for the product limits and exact unit values.
- Product maximums are listed in the policy maximum units table (do not exceed these limits).
- Examples of product maximums referenced in the policy: Berinert, Cinryze, Ruconest, Kalbitor, icatibant (see table).
Specialist prescribing or consultation required
Prescriber must be a relevant specialist (e.g., allergist, immunologist) or the record must document consultation with such a specialist. Requests lacking specialist prescribing or documented consultation may not meet medical necessity criteria.
- Acceptable documentation: specialist is the prescriber or a consultation note from an allergist/immunologist.
- This requirement applies to both initial and continuation requests.
Generic icatibant trial required for some branded products
Step therapy: For brand Firazyr, Sajazir, and Ruconest, patients 18 years and older must have tried and had an inadequate response to generic icatibant or have intolerance/contraindication/hypersensitivity to generic icatibant not expected with the requested product. Patients aged 13–17 are exempt from the generic icatibant trial requirement.
Site of care documentation for inpatient/outpatient hospital administration
Site‑of‑care documentation is required for administration in inpatient or outpatient hospital settings. Inpatient administration is permitted only when medical necessity is met and the admission is not solely for the purpose of giving the injection or infusion. For outpatient hospital administration, medical necessity must be met and one of the specified risk or situational criteria must be documented (e.g., history of severe adverse event to the product, conditions increasing risk for severe adverse event, uncontrolled/mild adverse events not managed with pre‑medication, inability to adhere to regimen, new to therapy or re‑initiation conditions, or change in product formulation). If site‑of‑care criteria are not met, administration should occur in a home‑based infusion or physician office setting.
- Inpatient: admission must not be solely to administer the drug.
- Outpatient hospital: document one qualifying risk/situation (listed in policy) to justify hospital setting.
- Alternatives: home‑based infusion or physician office administration if site‑of‑care criteria are not met.
Coding
Background & Evidence
Policy background: This policy governs use of FDA‑approved HAE therapies and has been reformatted to align diagnostic definitions with updated guidelines (renaming HAE type III to HAE with normal C1‑INH and updating diagnostic requirements). It specifies product‑specific age limits and clearly distinguishes prophylactic versus acute indications for each product, sets product maximum unit limits, and implements Site‑of‑Care rules (including bypasses for patients with prior severe adverse events or other increased risk conditions). The policy is reviewed annually by the Blue Cross NC P&T Committee.
Evidence and references: Primary references cited in the policy include FDA package inserts for the listed products and guideline publications: US HAE Association recommendations (2013), US HAEA Medical Advisory Board Guidelines (2020), the WAO/EAACI international guideline update (2021), and the updated international consensus on HAE with normal C1‑INH (2025).
| Term | Definition |
|---|---|
| HAE-C1INH Type 1 | HAE with low C4, low C1-INH antigen (protein), and low C1-INH function |
| HAE-C1INH Type 2 | HAE with low C4, normal or elevated C1-INH antigen, and low C1-INH function |
| HAE-nl-C1INH | HAE with normal C4 and normal C1-INH antigen and function; diagnosis via genetic confirmation or family history plus recurring angioedema attacks refractory to high-dose second generation H1 antihistamine therapy |
Revision History
Major April 2026 update: Reformatted diagnostic criteria to align HAE type I and II with updated guidelines; renamed HAE type III to HAE with normal C1-INH and adjusted diagnostic requirements to allow either documented genetic confirmation or recurring angioedema refractory to high-dose second generation H1 antihistamines plus family history for HAE-nl-C1INH. For acute treatments, removed requirement that patient must be experiencing at least one symptom of a moderate or severe HAE attack and adjusted placement of symptom examples. Added Sajazir (branded generic of Firazyr/icatibant) under existing J1744 HCPCS code. For brand Firazyr, Sajazir, and Ruconest, added requirement for trial and inadequate response to generic icatibant within initial and continuation criteria (with pediatric 13-17 exemption). Added requirement for use of self-administered product unless documented inability and lack of caregiver are met. For Cinryze continuation, added documentation confirming prophylactic use and demonstration of clinical benefit (examples provided). Added requirement to evaluate and discontinue medications known to cause angioedema where appropriate. Added specialist prescribing/consultation requirement and clarified examples of medications not to be used in combination. Adjusted product-specific maximum units. (Policy effective date 2026-04-01; last review 2026-04).
November 2025 update: Site of Care criteria updated to add additional bypasses for patients with history of severe adverse events or conditions increasing risk for severe adverse events to align with Place of Service for Medical Infusions policy.
April 2022 update: Removed requirement for two laboratory levels drawn at separate times for HAE-I diagnosis; clarified prophylactic use history (e.g., ≥2 attacks in last 2 months for Cinryze) and set Berinert age requirement to ≥5 years.
August 2021: Clarified requirement that patients not be treated with more than one anti-HAE medication for the same acute or preventative purpose (no change to policy intent).
June 2021: Changed diagnostic requirements; added restrictions for Ruconest regarding laryngeal attacks; prohibited concurrent use of another anti-HAE medication for prevention/treatment; added continuation criteria and maximum units; formatting changes.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.